
Faeth Therapeutics rose 23.2% from $8.14 to $10.03, ahead of the S&P 500's +13.3%. Its worst day was Nov 9 (−42.5%), and its low came Dec 15 at $7.89.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Faeth Therapeutics closed at its lowest level of the year, 3.1% below where the year started.
−4.4% · S&P 500 −0.2%
Faeth Therapeutics shares rose 187.5%, while the S&P 500 rose 0.5%.
+187.5%, the year's best day, on 13M shares, the year's heaviest volume · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
EPS of $-3.74 beat the $-4.81 estimate on $0.00 revenue.
−9.2% · S&P 500 −0.3%
EPS of $-131.45 missed the $-0.62 estimate on $0.00 revenue.
+3.1% · S&P 500 −1.2%
EPS of $-2.84 beat the $-4.77 estimate on $0.00 revenue.
−6.7% · S&P 500 +1.8%
Faeth Therapeutics closed at its highest level of the year, 392.0% above where the year started.
+2.7% · S&P 500 −0.4%
EPS of $-0.79 missed the $-0.70 estimate on $0.00 revenue.
+2.2% · S&P 500 +0.3%
Where it ended: a close of $10.03 on Nov 13, 2026.
Nothing in the past 12 months.
All FTH dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for FTH and SPY from Benzinga historical bars. Not investment advice.